Pharming (PHAR) FCF Margin (2020 - 2026)
Pharming's (PHAR) quarterly FCF Margin came in at 10.76% in Q4 2025, up 49145330.0% YoY from N/an in Q4 2024, and up 100.0% on a QoQ basis from 491442.54% in Q4 2024.
Powered by 
Analysis
Pharming (PHAR) FCF Margin (2020 - 2026) Analysis & Trends
Pharming (PHAR) has 6 years of FCF Margin data on file, last reported at 10.76% in Q4 2025.
- Quarterly FCF Margin rose 49145330.0% year-over-year to 10.76% in Q4 2025, while the trailing twelve-month figure through Jun 2026 was 3.13% (down 838.0% YoY) and the FY2025 annual result came in at 14.35%, up 1522.0% from the prior year.
- FCF Margin improved to 10.76% in Q4 2025, from 491442.54% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 13513368.98% in Q3 2024 to a low of 19538177.34% in Q4 2023.
- A 5-year average of 651619.59% and a median of 3.03% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin plunged 1953817788 bps — and 2024, when it surged 1904673480 bps.
- Tracing PHAR's FCF Margin over 5 years: stood at 0.03% in 2021, then soared by 1708 bps to 0.54% in 2022, then slumped by 2000000000 bps to 19538177.34% in 2023, then soared by 97 bps to 491442.54% in 2024, then soared by 100 bps to 10.76% in 2025.
- The last three FCF Margin figures came in at 10.76% (Q4 2025), 491442.54% (Q4 2024), and 13513368.98% (Q3 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Pharming | 794.84 Mn | 635.34 Mn | 141.47 Mn | -4.54% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.54% |
| Dec 31, 2025 | 10,756,807.51% |
| Dec 31, 2024 | -0.49% |
| Sep 30, 2024 | 13.51% |
| Jun 30, 2024 | -27,765,182.19% |
| Dec 31, 2023 | -19.54% |
| Sep 30, 2023 | 5.51% |
| Jun 30, 2023 | -57.23% |
| Dec 31, 2022 | 1.31% |
| Sep 30, 2022 | 23.91% |
| Dec 31, 2021 | 0.05% |
| Sep 30, 2021 | 14.30% |
| Dec 31, 2020 | -67.42% |
| Sep 30, 2020 | 32.58% |